retatrutide fda approval 2025 Extreme Side Effects Followed Overdose of Unapproved Weight-Loss Drug Retatrutide and the Grey Market:

Placebocontrolled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

While the first GLP-1 was approved by the FDA more than 20 years ago, to treat Type 2 diabetes, the use of these drugs took off in 2021 when Novo Nordisk received approval for a semaglutide drug to treat obesity, with the brand name Wegovy

Our findings at this time therefore support a role for inulin in weight loss, as opposed to weight-loss maintenance

3- Alpha-synuclein, LRRK2 and GBA are emerging as some of the most important biologic targets in the pipeline